This session is designed to provide the necessary background and data that supports the use of ctDNA and MRD in oncology. Circulating tumor DNA (ctDNA), a form of liquid biopsy, is a noninvasive method that has become a reliable tool in oncology, both in solid tumors and hematologic malignancies. Over 850 clinical trials are currently recruiting for studies involving the use of ctDNA in solid tumor malignancies and over 1200 clinical trials involving the use of MRD in hematologic malignancies. The use of ctDNA and MRD is transforming how we detect, monitor, and determine treatment across a variety of malignancies. The increasing integration of ctDNA in clinical practice has been seen in the most common solid and hematologic malignancies and is therefore vital for oncology pharmacists to understand the data to support current and future applications of ctDNA and minimal residual disease (MRD). The BCOP Clinical Sessions are part of the professional development program for the recertification of board-certified oncology pharmacists by the Board of Pharmacy Specialties and jointly provided by ACCP and the American Society of Health-System Pharmacists (ASHP). In order to earn the BCOP recertification credit, participants must attend the session, claim the continuing pharmacy education credit, and pass the associated posttest. Access to the BCOP Clinical Sessions posttests will be available on December 14, 2022, at www.accp.com/myaccount to anyone who has purchased access to the BCOP posttests. For participants who have not purchased access to the posttest, access can be purchased until 5:30 p.m. on Tuesday, October 18, at the ACCP Registration Desk. The deadline to submit posttests for these sessions will be December 12, 2023.